ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional Results available

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

ClinicalTrials.gov ID: NCT02811861

Public ClinicalTrials.gov record NCT02811861. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 2:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR)

Study identification

NCT ID
NCT02811861
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Eisai Inc.
Industry
Enrollment
1,069 participants

Conditions and interventions

Interventions

  • Everolimus Drug
  • Lenvatinib Drug
  • Pembrolizumab Drug
  • Sunitinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 12, 2016
Primary completion
Aug 27, 2020
Completion
Mar 30, 2027
Last update posted
Feb 22, 2026

2016 – 2027

United States locations

U.S. sites
35
U.S. states
16
U.S. cities
32
Facility City State ZIP Site status
Stanford School of Medicine Stanford California 94305-5826
Boca Raton Community Hospital Boca Raton Florida 33486
Florida Cancer Specialists Fort Myers Florida 33901
University of Miami Miami Florida 33136
Mount Sinai Medical Center Miami Beach Florida 33136
Florida Hospital Cancer Institute Orlando Florida 32804
Florida Cancer Specialists ( North Region) St. Petersburg Florida 33705
Florida Cancer Specialists West Palm Beach Florida 33401
Joliet Oncology - Hematology Associates Joliet Illinois 60435
Healthcare Research Network III, LLC Tinley Park Illinois 60487
Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC Overland Park Kansas 66209
Cotton-Oneil Clinical Research Center Topeka Kansas 66604
Ochsner Clinic Foundation New Orleans Louisiana 70121
Associates in Oncology & Hematology, PC Bethesda Maryland 20817
Massachusetts General Hospital- MGH Boston Massachusetts 02214
Dana Farber Cancer Institute Boston Massachusetts 02215
Karmanos Cancer Center Detroit Michigan 48201
GU Research Network Omaha Nebraska 68130
Nebraska Cancer Specialists Omaha Nebraska 68130
Hackensack Medical Center Hackensack New Jersey 07601
Rosewell Park Cancer Institute Buffalo New York 14263
Broome Oncology Johnson City New York 13790
Weill Cornell Medical College New York Presbyterian Hospital New York New York 10021
Memorial Sloan Kettering Cancer Center New York New York 10065
Montefiore Medical Center The Bronx New York 10461
Mission Hospital_ Cancer Care of Western North Carolina Asheville North Carolina 28801
Oncology Hematology Care Cincinnati Ohio 45242
Medical University of South Carolina Charleston South Carolina 29412
SCRI - Tennessee Oncology Nashville Tennessee 37203
Texas Oncology, P.A. Dallas Texas 75231
Texas Oncology PA Fort Worth Texas 76104
Texas Oncology PA - McAllen McAllen Texas 78503
Texas Oncology PA - Paris Paris Texas 75460
USOR Texas Oncology The Woodlands Texas 77380
Texas Oncology PA - Tyler Tyler Texas 75702

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 148 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02811861, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 22, 2026 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02811861 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →